The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Rechallenge may not necessarily lead to relapse of AE/ILD
Publications
Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018 Dec 20;;1078155218820580 — 2018 Dec 20 — 1078155218820580
Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
BMC pulmonary medicine 2017 Dec 06;17;173 — 2017 Dec 06 — 173